NCT02128906View on ClinicalTrials.gov

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 23, 2013

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Squamous Cell Carcinoma
Interventions
DRUG

Cisplatin

Cisplatin 40 mg/m2 weekly x 7

RADIATION

IMRT

IMRT: once daily, M-F, 7 weeks (70 Gy)

DRUG

Docetaxel

Docetaxel 15 mg/m2 weekly x 7

DRUG

Cetuximab

Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center - Radiation Oncology, Pittsburgh

All Listed Sponsors
lead

Christopher Wilke

OTHER